Moreover, in the CRESTONE study (NCT04383210) in the cohort of NSCLC patients harboring NRG1 fusions who received seribantumab, the ORR and the disease control rate were 39% and 94%, respectively. The gene discussed is NRG1; the disease is non-small cell lung carcinoma.